Corona Remedies

Which are the latest news on Corona Remedies?

Why is Corona Remedies Ltd falling/rising?

As of 05-Sep, the stock price of Corona Remedies Ltd is currently at 2,099.90, reflecting a decline after two days of gains and underperforming its sector. Despite a year-to-date increase of 51.52%, concerns over high valuation and recent price movements are contributing to its current downward trend.

As of 05-Sep, the stock price of Corona Remedies Ltd is falling, currently at 2,099.90, reflecting a decrease of 24.45 or 1.15%. This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed its sector by 0.98% today, indicating weaker performance relative to its peers.<BR><BR>In terms of recent performance, the stock has shown a slight increase of 0.81% over the past week, contrasting with a decline of 3.08% over the past month. Year-to-date, however, it has performed well, with a significant increase of 51.52%, while the benchmark Sensex has decreased by 10.21% in the same period.<BR><BR>Despite the current price drop, there are positive indicators such as rising investor participation, with a notable increase in delivery volume by 32.18% against the 5-day average. Additionally, institutional investors have increased their stake in the company by 7.27% over the previous quarter, suggesting confidence in the company's long-term prospects.<BR><BR>However, the stock's valuation is considered very expensive, with a high enterprise value to capital employed ratio of 14.9, which may contribute to the current price decline as investors reassess the stock's value in light of its performance metrics. Overall, while there are strong fundamentals and positive growth indicators, the combination of recent price movements and valuation concerns appears to be influencing the stock's current downward trend.

What does Corona Remedies do?

Corona Remedies Ltd is a small-cap pharmaceutical company, incorporated in 2004, with net sales of 422 Cr and a net profit of 60 Cr as of June 2026. It has a market cap of INR 12,492 Cr and key metrics include a P/E ratio of 59.00 and a return on equity of 26.75%.

Overview:<BR>Corona Remedies Ltd is a small-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>The company was originally incorporated as CORONA Remedies Private Limited in 2004 and later converted to a public limited company. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 422 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 60 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 12,492 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 59.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.48% <BR>Debt-Equity: 0.16 <BR>Return on Equity: 26.75% <BR>Price to Book: 16.97<BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Corona Remedies?

Peers of Corona Remedies include Concord Biotech, Natco Pharma, Marksans Pharma, Jubilant Pharmo, Akums Drugs, Viyash Scientifi, Blue Jet Health, Sanofi Consumer, and P & G Health Ltd. Marksans Pharma leads with a 1-year return of 91.38%, while Sanofi Consumer has the lowest at -20.12%.

Peers: The peers of Corona Remedies are Concord Biotech, Natco Pharma, Marksans Pharma, Jubilant Pharmo, Akums Drugs, Viyash Scientifi, Blue Jet Health, Sanofi Consumer, and P & G Health Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, Natco Pharma, Marksans Pharma, Blue Jet Health, Sanofi Consumer, and P & G Health Ltd, while Average management risk is found at Jubilant Pharmo and Akums Drugs. Below Average management risk is noted for Viyash Scientifi. Growth is rated as Good for Viyash Scientifi, while Below Average growth is seen in Concord Biotech, Natco Pharma, Marksans Pharma, Jubilant Pharmo, and the rest. Average growth is reported for Akums Drugs. Excellent capital structure is present in Concord Biotech, Natco Pharma, Marksans Pharma, Akums Drugs, Blue Jet Health, Sanofi Consumer, and P & G Health Ltd, while Average capital structure is found at Jubilant Pharmo and the rest.<BR><BR>Return Snapshot: Marksans Pharma has the highest 1-year return at 91.38%, while Sanofi Consumer has the lowest at -20.12%. Corona Remedies' 1-year return is not available for comparison. Additionally, Sanofi Consumer is the only peer with a negative six-month return.

How big is Corona Remedies?

As of 31st August, Corona Remedies Ltd has a market capitalization of 12,492.00 Cr, with recent net sales of 1,479.07 Cr and a net profit of 199.03 Cr. Shareholder's funds were 746.86 Cr, and total assets amounted to 1,205.14 Cr for the annual period ending March 2026.

As of 31st August, Corona Remedies Ltd has a market capitalization of 12,492.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 1,479.07 Cr and a Net Profit of 199.03 Cr.<BR><BR>For the latest annual period ending March 2026, the Shareholder's Funds were 746.86 Cr, while the Total Assets amounted to 1,205.14 Cr.

Should I buy, sell or hold Corona Remedies Ltd?

Are Corona Remedies Ltd latest results good or bad?

Corona Remedies Ltd's latest results show strong profit and revenue growth, with a net profit of ₹45.33 crore and a revenue increase of 20.23% year-on-year. However, the significant decline in operating margins raises concerns about operational efficiency and sustainability moving forward.

The latest results for Corona Remedies Ltd indicate a mixed performance. On the positive side, the company reported a consolidated net profit of ₹45.33 crore for Q4 FY26, which is a significant increase of 43.68% year-on-year and a 9.84% rise quarter-on-quarter. Additionally, revenue grew to ₹353.09 crore, reflecting a year-on-year increase of 20.23% and a sequential growth of 3.12%. <BR><BR>However, there are notable concerns regarding operational efficiency. The operating margin, which declined to 17.56%, represents a sharp drop of 673 basis points from the previous quarter, indicating significant margin compression. This decline is attributed to rising employee costs, which increased substantially and outpaced revenue growth.<BR><BR>Overall, while the company has shown strong profit and revenue growth, the deterioration in margins raises questions about the sustainability of this performance. Investors should monitor how the company addresses these margin pressures in future quarters.

Has Corona Remedies Ltd declared dividend?

Yes, Corona Remedies Ltd has declared a 100% dividend with an ex-date of June 19, 2026. However, the dividend yield is 0%, and total returns have been mixed, with a 7.52% return in the last 3 months but no returns over longer periods.

Corona Remedies Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Ex-date: 19 Jun 26<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 7.52%, the dividend return was 0%, resulting in a total return of 7.52%.<BR><BR>Over the last 6 months, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 2 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 3-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Corona Remedies Ltd has declared a dividend, the dividend yield remains at 0%, indicating that there has been no effective return from dividends in recent years. The total returns over various periods show a mixed performance, with a notable return in the last 3 months but no returns in the longer periods.